Literature DB >> 17034951

Biochemical characterization and molecular cloning of a plasminogen activator proteinase (LV-PA) from bushmaster snake venom.

Eladio F Sanchez1, Liza F Felicori, Carlos Chavez-Olortegui, Henrique B P Magalhaes, Ana L Hermogenes, Marcelo V Diniz, Inacio de L M Junqueira-de-Azevedo, Arinos Magalhaes, Michael Richardson.   

Abstract

The protein (LV-PA) from bushmaster (Lachesis muta muta) venom is a serine proteinase which specifically activates the inactive proenzyme plasminogen. LV-PA is a single chain glycoprotein with an apparent molecular mass of 33 kDa that fell to 28 kDa after treatment with N-Glycosidase F (PNGase F). Approximately 93% of its protein sequence was determined by automated Edman degradation of various fragments derived from a digestion with trypsin. A cDNA library of L. m. muta was constructed to generate expressed sequence tags (ESTs) and the plasminogen activator precursor cDNA was sequenced. The complete amino acid sequence of the enzyme was deduced from the cDNA sequence. LV-PA is composed of 234 residues and contains a single asparagine-linked glycosylation site, Asn-X-Ser, bearing sugars that account for approximately 10% of the enzyme's total molecular mass of 33 kDa. The sequence of LV-PA is highly similar to the plasminogen activators (PAs) TSV-PA from Trimeresurus stejnegeri venom and Haly-PA from Agkistrodon halys. Furthermore, the mature protein sequence of LV-PA exhibits significant similarity with other viperidae venom serine proteinases which affect many steps of hemostasis, ranging from the blood coagulation cascade to platelet function. The Michaelis constant (Km) and the catalytic rate constant (kcat) of LV-PA on four chromogenic substrates were obtained from Lineweaver-Burk plots. In addition, we used an indirect enzyme-linked immunoabsorbent assay (ELISA) to explore the phylogenetic range of immunological cross-reactivity (using antibodies raised against LV-PA) with analogous serine proteinases from two viperidae venoms and mammals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17034951     DOI: 10.1016/j.bbagen.2006.08.023

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  6 in total

1.  Anti-coagulant activity of a metalloprotease: further characterization from the Indian cobra (Naja naja) venom.

Authors:  M S Kumar; V R Devaraj; B S Vishwanath; K Kemparaju
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

2.  Sulfated Galactan from Palisada flagellifera Inhibits Toxic Effects of Lachesis muta Snake Venom.

Authors:  Ana Cláudia Rodrigues da Silva; Luciana Garcia Ferreira; Maria Eugênia Rabello Duarte; Miguel Daniel Noseda; Eladio Flores Sanchez; André Lopes Fuly
Journal:  Mar Drugs       Date:  2015-06-11       Impact factor: 5.118

3.  Subproteome of Lachesis muta rhombeata venom and preliminary studies on LmrSP-4, a novel snake venom serine proteinase.

Authors:  Gisele A Wiezel; Karla Cf Bordon; Ronivaldo R Silva; Mário Sr Gomes; Hamilton Cabral; Veridiana M Rodrigues; Beatrix Ueberheide; Eliane C Arantes
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2019-04-15

4.  Comprehensive Study of the Proteome and Transcriptome of the Venom of the Most Venomous European Viper: Discovery of a New Subclass of Ancestral Snake Venom Metalloproteinase Precursor-Derived Proteins.

Authors:  Adrijana Leonardi; Tamara Sajevic; Jože Pungerčar; Igor Križaj
Journal:  J Proteome Res       Date:  2019-04-24       Impact factor: 4.466

Review 5.  Biomedical applications of snake venom: from basic science to autoimmunity and rheumatology.

Authors:  Carlos A Cañas; Santiago Castaño-Valencia; Fernando Castro-Herrera; Felipe Cañas; Gabriel J Tobón
Journal:  J Transl Autoimmun       Date:  2020-12-14

Review 6.  Bioactive Molecules Derived from Snake Venoms with Therapeutic Potential for the Treatment of Thrombo-Cardiovascular Disorders Associated with COVID-19.

Authors:  Fatah Chérifi; Fatima Laraba-Djebari
Journal:  Protein J       Date:  2021-09-09       Impact factor: 2.371

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.